Almost every low figure on this site’s price desk belongs to a compounded preparation, and the price difference against an approved product is not a discount on the same thing. It is a different regulatory route with a different set of things known about it. That is worth setting out plainly before any figure is compared on the price check.
What "compounded" changes
A compounded incretin does not go through FDA approval[1]. A committee convened by the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy reviewed the role of these products and reported limited data showing positive clinical outcomes in small cohorts, alongside significant legal and safety concerns[1]. Its practical advice was to help patients obtain approved medications where possible, and where they choose a compounded product, to use reputable pharmacies and monitor for safety and efficacy[1].
The shortage ended, and the rules changed with it
While a drug is on the FDA shortage list, compounding pharmacies have latitude to prepare copies of it. With the innovator semaglutide and tirzepatide shortages resolved, that latitude closed: compounders may legally sell only products that are not essentially copies, meaning a different route of administration, a different dose, or added ingredients[2].
That rule is visible in what is now on sale. A search of compounding sites between February and March 2025 identified 33 unique semaglutide or tirzepatide products[2]. Two-thirds contained semaglutide and one-third tirzepatide. Forty-eight percent combined the peptide with some mixture of cyanocobalamin, glycine, niacinamide, docusate or ondansetron, and the 17 single-ingredient products were sublingual in 82% of cases or orally disintegrating tablets in the remaining 18%[2].
What the safety reporting shows
A retrospective analysis of the FDA Adverse Event Reporting System covering 2018 to 2024 examined 81,078 GLP-1 reports, of which 707 involved compounded products[3]. Compounded formulations showed higher reporting odds ratios for abdominal pain, 2.84 (95% CI 2.29 to 3.49), and for cholecystitis, 3.39 (95% CI 1.61 to 6.31)[3].
The larger differences were in how the product reached the patient rather than in the molecule. Reporting odds were 48.92 (95% CI 12.63 to 189.6) for preparation errors and 19.00 (95% CI 4.24 to 85.03) for contamination, and the odds of hospitalization were 2.35 (95% CI 1.94 to 2.83)[3]. Administration and dosing errors were reported less often for compounded products.
Why the price on a compounded page is not the price of the same thing
Nothing above says a compounded preparation does not work. It says that whether it works as well, at the same dose, with the same impurity profile, has not been established the way it has for the approved product, and that the products currently sold are deliberately not the same formulation[2]. A page comparing a $99 compounded figure with a $499 branded one is comparing two purchases that differ in what is known about them as much as in cost — a split visible at ShedRx, which sells both, and at WeightWatchers Clinic, which sells only the approved products.
The practical checks available to a buyer are the ones the cited opinion names: whether the pharmacy is identified, whether a beyond-use date and storage conditions are published, and whether a milligram dose appears beside the price[1]. On the products surveyed, those last two were published by 18% and 28% respectively[2]. Which of them each seller publishes is recorded on the seller reviews, against the rules in the methodology.